We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TCMD:NASDAQTactile Systems Technology, Inc. Analysis

Data as of 2026-05-26 - not real-time

$25.06

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Tactile Systems Technology (TCMD) is trading around $25.06, well below its DCF‑derived fair value of $51.33, implying an upside of roughly 57% if the model holds. The company posted a robust 22.8% revenue growth YoY, driven by strong demand for its pneumatic compression devices, and maintains an impressive 76% gross margin despite a modest negative operating margin. Forward earnings estimates suggest a forward PE of 16.65, markedly lower than the trailing PE of 28.8 and the industry average PE of 27.4, reinforcing the undervalued narrative. Analyst sentiment is overwhelmingly positive, with a Zacks Rank 1 Strong Buy and a median price target of $40, reflecting a potential 60%+ price appreciation.
Technical indicators are supportive: the stock sits above its 20‑day (24.01) and 50‑day (24.92) SMAs, the MACD histogram is positive indicating bullish momentum, and the RSI at 53 signals a neutral but not overbought condition. Volatility remains high at nearly 49% (30‑day) and beta is modest at 0.73, suggesting price swings but limited market‑wide correlation. Recent upgrades from B. Riley and Zacks, coupled with decreasing volume trends, point to a cautious yet optimistic short‑term outlook.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above short‑term SMAs indicating bullish bias
  • Analyst upgrades and strong buy recommendation
  • Support level at $20.53 provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued DCF fair value with ~57% upside
  • Robust revenue growth and high gross margins
  • Forward PE compression to 16.6 suggests earnings acceleration

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained market demand for chronic‑disease medical devices
  • Strong cash position relative to modest debt
  • Long‑term upside potential reflected in analyst price targets

Key Metrics & Analysis

Financial Health

Revenue Growth22.80%
Profit Margin5.91%
P/E Ratio28.8
ROE9.59%
ROA7.31%
Debt/Equity6.96
P/B Ratio2.6
Op. Cash Flow$42.1M
Free Cash Flow$33.5M
Industry P/E27.4

Technical Analysis

TrendNeutral
RSI53.6
Support$20.53
Resistance$27.57
MA 20$24.01
MA 50$24.92
MA 200$22.90
MACDBullish
VolumeDecreasing
Fear & Greed Index91.05

Valuation

Fair Value$51.33
Target Price$39.50
Upside/Downside57.62%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.73
Volatility48.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.